9 results
-
Refers to the proportion of brain OGA enzyme bound by FNP-223, measured via PET imaging.
Reference:
Pokorny R. Brain target engagement and pharmacokinetic-enzyme occupancy (PK-EO) relationship of FNP-223: a novel oral OGA inhibitor for progressive supranuclear palsy – phase 1 PET study. Poster presented at: MDS Congress; 2025 Oct 5-9; Honolulu, HI, USA
-
Tau protein is a protein in the cytoskeleton of neurons that is key to stabilizing microtubules, which act as axonal transport pathways and form part of the neuronal structure. In tauopathies, tau protein loses its normal function, and forms NFTs, which disrupt cellular transport and lead to neurodegeneration and neuronal death. Loss of normal tau function and abnormal aggregation are central to PSP pathophysiology; and the modulation of tau O-GlcNAcylation is a therapeutic strategy under investigation.
Reference:
Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28. doi:10.1186/s13024-022-00533-z
-
a group of neurodegenerative disorders characterized by tau deposits in the brain, with symptoms of dementia and parkinsonism.
Reference:
Zhang Y, Wu KM, Yang L, Dong Q, Yu JT. Tauopathies: new perspectives and challenges. Mol Neurodegener. 2022;17(1):28. doi:10.1186/s13024-022-00533-z
-
The remote monitoring and recording of physiological parameters, such as heart rate or ECG, to assess a patient’s long-term functions in real time.
Reference:
ScienceDirect Topics. Telemetry [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/agricultural-and-biological-sciences/telemetry
-
The elapsed time after drug administration at which the highest concentration of the drug in plasma (Cmax) is observed.
Reference:
REVIVE. Tmax (time to peak drug concentration) [Internet]. [cited 2026 Jan]. Available from: https://revive.gardp.org/resource/tmax-time-to-peak-drug-concentration/?cf=encyclopaedia
-
The degree to which adverse effects of a treatment can be tolerated by patients without experiencing significant adverse events.
Reference:
ScienceDirect Topics. Tolerability [Internet]. [cited 2025 Nov]. Available from: https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/tolerability
-
A radioactive compound used in PET imaging to bind selectively a protein. For example, the [18F]-IMA601 binds to the O-GlcNAcase (OGA) enzyme, allowing visualization and measurement of OGA distribution and target engagement in the brain.
Reference:
Pokorny R. Brain target engagement and pharmacokinetic-enzyme occupancy (PK-EO) relationship of FNP-223: a novel oral OGA inhibitor for progressive supranuclear palsy – phase 1 PET study. Poster presented at: MDS Congress; 2025 Oct 5-9; Honolulu, HI, USA | Radiopaedia.org. PET radiotracers [Internet]. [cited 2025 Nov]. Available from: https://radiopaedia.org/articles/pet-radiotracers
-
an adverse event that appears or worsens during a clinical trial. It helps identify events that are temporally associated with the drug.
Reference:
Association of Health Care Journalists. Treatment emergent adverse event (TEAE) [Internet]. [cited 2025 Nov]. Available from: https://healthjournalism.org/glossary-terms/treatment-emergent-adverse-event-teae/
-
A distinct type of astrocytic pathology characterized by the presence of dense, argyrophilic (silver stain-positive) phosphorylated tau-immunopositive inclusions within the proximal processes of astrocytes. Tufted astrocytes are a histopathological hallmark of PSP.
Reference:
Kovacs GG. Astroglia and tau: new perspectives. Front Aging Neurosci. 2020;12:96. doi:10.3389/fnagi.2020.00096
